Online citations, reference lists, and bibliographies.
← Back to Search

Preoperative Evaluation Of Patients With Malignant Pleural Mesothelioma: Role Of Integrated CT-PET Imaging

M. Truong, E. Marom, J. Erasmus
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is an uncommon neoplasm arising from mesothelial cells of the pleura. The prognosis is poor with a median survival of 8 to 18 months after diagnosis. Multimodality regimens combining chemotherapy, radiotherapy, immunotherapy, and surgery are being used more frequently in patient management. Extrapleural pneumonectomy is the surgical treatment of choice in 10% to 15% of patients who present with resectable disease and is reported to prolong survival. Accurate staging is important to distinguish patients who are resectable from those requiring palliative therapy. Integrated computed tomography-positron emission tomography (CT-PET) increases the accuracy of overall staging in patients with MPM and significantly improves the selection of patients for curative surgical resection. Specifically, CT-PET detects more extensive disease involvement than that shown by other imaging modalities and is particularly useful in identifying occult distant metastases. This article reviews aspects of imaging performed in the initial staging of patients with MPM according to the International Mesothelioma Interest Group staging system and will emphasize the appropriate role of CT-PET imaging in determining the T, N, and M descriptors.
This paper references
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics
Z J Wang (2004)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
Evaluation of patients with known mesothelioma with 18F-fluorodeoxyglucose and PET. Comparison with computed tomography
J Zubeldia (2000)
10.1136/oem.2003.010165
Changing trends in US mesothelioma incidence
H. Weill (2004)
10.1159/000224951
Chemotherapy of malignant mesothelioma.
R. Gerner (1974)
10.1148/RG.241035058
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
Z. Wang (2004)
10.1016/0169-5002(94)00404-B
Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients.
L. Tammilehto (1995)
10.1165/AJRCMB.26.2.4673
The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor.
P. Cacciotti (2002)
Why most PET of lung and head-and-neck cancer will be PET/CT.
G. Goerres (2004)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1586/14737140.4.3.361
Pemetrexed (Alimta®): improving outcomes in malignant pleural mesothelioma
Leanne S Budde (2004)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
10.1053/SONC.2002.30230
Multimodality treatment of diffuse malignant pleural mesothelioma.
L. Zellos (2002)
10.1093/AJE/KWH025
Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.
B. Price (2004)
10.2214/AJR.159.5.1414807
Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability.
E. Patz (1992)
10.1016/S0022-5223(96)70342-2
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
10.1136/thorax.58.12.1077
Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma
V. Gerbaudo (2003)
10.1053/SONC.2002.30234
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.
A. Nowak (2002)
10.1186/1477-7819-1-11
Desmoid tumors of the abdominal wall: A case report
M. Overhaus (2003)
10.3816/CLC.2004.N.008
Integration of multimodality approaches in the management of malignant pleural mesothelioma.
Derlis Martino (2004)
Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.
V. Gerbaudo (2002)
10.1067/MTC.2000.106529
Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
D. Schneider (2000)
10.1186/1477-7819-2-11
Multimodal treatment for resectable epithelial type malignant pleural mesothelioma
I. Yoshino (2004)
10.1016/J.CRITREVONC.2003.10.001
Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments.
A. Catalano (2004)
10.1378/CHEST.107.6_SUPPLEMENT.332S
Current approach to malignant mesothelioma of the pleura.
J. Aisner (1995)
10.1016/J.ATHORACSUR.2005.06.014
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
D. Rice (2005)
10.1089/108497804323071913
Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
C. Nanni (2004)
Chemotherapy for malignant mesothelioma.
R. Taub (1997)
10.1016/S0003-4975(03)00010-9
The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma.
J. H. Schouwink (2003)
10.1053/SONC.2002.30228
The role of imaging in malignant pleural mesothelioma.
E. Marom (2002)
10.1007/S11912-002-0009-Z
p53 Gene therapy for lung cancer
S. Swisher (2002)
10.1093/OXFORDJOURNALS.AJE.A118528
INVESTIGATIONS ON THE CONTROL OF HOOKWORM DISEASE. VI.A STUDY OF THE EFFECT OF HOOKWORM CONTROL MEASURES ON SOIL POLLUTION AND INVESTIGATION IN A SUGAR ESTATE
W. W. Cort (1922)
10.2214/AJR.172.4.10587144
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
10.1016/J.LUNGCAN.2005.03.006
Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging.
H. Steinert (2005)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.2214/AJR.166.2.8553940
The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging.
E. Patz (1996)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1016/S1095-0397(00)00077-7
11. Evaluation of Patients with Known Mesothelioma with 18F-Fluorodeoxyglucose and PET. Comparison with Computed Tomography.
Zubeldia (2000)
10.1007/S11912-003-0076-9
Advances in the management of malignant mesothelioma
Mazen Y. Khalil (2003)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/J.LUNGCAN.2005.03.007
The role of PET in the surgical management of malignant pleural mesothelioma.
R. Flores (2005)
10.1378/CHEST.114.3.713
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)
10.5555/URI:PII:0093775481900403
Clinical presentation and natural history of benign and malignant mesothelioma.
K. Antman (1981)



This paper is referenced by
10.1245/s10434-008-9899-9
Surgical Treatment in the Management of Malignant Pleural Mesothelioma: A Single Institution’s Experience
J. Sandick (2008)
10.1016/j.crad.2009.03.010
CT appearances of pleural tumours.
H. Salahudeen (2009)
10.1007/s11748-007-0243-2
Malignant mesothelioma: current status and perspective in Japan and the world
S. Hasegawa (2008)
10.1016/j.crad.2016.05.001
Evidence-based indications for the use of PET-CT in the United Kingdom 2016.
S. Barrington (2016)
10.1159/000262458
FDG-PET/CT in lung cancer: an update.
R. Baum (2010)
10.1016/S1579-2129(07)60128-1
[Usefulness of positron emission tomography-computed tomography in respiratory medicine].
A. Maldonado (2007)
10.4046/TRD.2009.67.4.369
Malignant Mesothelioma Presenting as Large Neck Mass
B. Y. Lee (2009)
10.2214/AJR.11.7076
Spectrum of malignant pleural and pericardial disease on FDG PET/CT.
W. Makis (2012)
10.1007/s11307-009-0254-8
Letter to the Editor
V. Gerbaudo (2009)
10.1097/RTI.0b013e318156eb39
F-18 fluorodeoxyglucose PET/CT scanning in the diagnostic work-up of a primary pericardial mesothelioma: a case report.
P. Ost (2008)
10.1097/JTO.0b013e31819f2e0e
Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure
H. Roberts (2009)
10.1016/J.EJRNM.2016.12.011
Value of contrast CT in combination with PET/CT in mesothelioma staging: Optimal protocol for initial assessment
M. Houseni (2017)
10.1007/S11307-009-0254-8
Primary lesions were more 18F-FDG avid in patients with distant spread than in those without extensive disease.
Victor H. Gerbaudo (2009)
10.1007/s11307-009-0203-6
Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
La tomografía por emisión de positrones en patología quirúrgica del tórax. Una revisión
J. L. Olavarrieta (2008)
10.5772/31195
Monitoring of chemotherapy response in malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography.
T. Kimura (2008)
10.1007/s11307-009-0255-7
Letter to the Editor
S. Lee (2009)
10.1007/978-1-4419-0787-5_1
Diagnostic Imaging of Lung and Pleural Tumors
P. Groot (2013)
10.2214/AJR.11.7015
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
R. Gill (2012)
10.1586/era.09.2
Future developments in the management of malignant pleural mesothelioma
Paolo Andrea Zucali (2009)
10.1136/thx.2007.087619
BTS statement on malignant mesothelioma in the UK, 2007
(2007)
10.1016/B978-1-4160-3624-1.00001-9
1 – Imaging Tumors of the Lung and Pleura
E. Marom (2010)
10.1157/13110882
Utilidad de la tomografía por emisión de positrones-tomografía computarizada (PET-TC) en neumología
A. Maldonado (2007)
10.1148/RG.271065105
Best cases from the AFIP: Malignant mesothelioma.
Sean M Tyszko (2007)
Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
A. Abakay (2013)
10.1634/THEONCOLOGIST.12-7-850
Multidisciplinary treatment of malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1007/s00423-009-0476-x
Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy
B. Buchholz (2009)
10.5455/JTOMC.2016.05.066
F-18 FDG PET/CT in primary and metastatic pleural involvement -
Gul Ege Aktaş (2017)
10.1097/BRS.0b013e3181ae8294
Malignant Pleural Mesothelioma Presenting as Low Back Pain: Diagnosed by Bone Scan Coordinating With F-18 FDG PET/CT
Y. Huang (2009)
10.1200/JCO.2007.10.7086
Pleural mesothelioma metastatic to tongue.
Daniel S Higginson (2007)
10.1007/s00066-011-2234-6
PET-guided dose escalation tomotherapy in malignant pleural mesothelioma
Andrei Fodor (2011)
[Contemporary imaging of pericardial diseases. Part 2. Expert consensus statement of the Polish Clinical Forum for Cardiovascular Imaging].
A. Gackowski (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar